###### Key questions

What is already known?
======================

-   There is rising concern about the accountability, patient safety and sustainability of short-term reconstructive surgical missions; however, data on these parameters are lacking.

What are the new findings?
==========================

-   Evidence provided by research on surgical outcomes is limited and of low quality, and the safety of missions is likely to be overestimated by studies in which the quality of follow-up is not reported. Our data suggest that engagement in sustainable development of the local healthcare system and the feasibility of conducting high-quality, long-term follow-up go hand in hand.

What do the new findings imply?
===============================

-   We call for implementing longer-term outcome research of future missions.

-   One approach that could provide a framework to conduct such research, is to implement diagonal development missions. These missions combine the positive impact of the short-term vertical inputs (e.g. providing surgical services) and long-term horizontal investments (e.g. development of sustainable healthcare systems), with the aim of improving access to, and capacity of, the local surgical healthcare systems in the long-term.

Introduction {#s1}
============

Conditions that are treatable by reconstructive surgery make up a large part of the global burden of surgical disease. Examples are burns (8.1 million disability-adjusted life years \[DALYs\]),[@R1] orofacial clefts (0.23 million DALYs),[@R1] complex wounds including trauma-related wounds (unknown DALYs, but estimated to be significant), pressure sores (0.67 million DALYs)[@R1] or noma (a neglected tropical disease, a roughly estimated 1--10 million DALYs).[@R2] Short-term reconstructive surgical missions are a well-established routine method of addressing these conditions and reducing their impact on global health by providing specialised care in underserved populations.[@R3] Such missions are commonly short term, disease specific, focus on service delivery and have a tendency to work outside the local healthcare system. This is also referred as a 'vertical approach to healthcare development'.[@R4]

Despite being a common model, the impact of reconstructive surgical missions is hardly known.[@R5] Medical missions in general are commonly debated in the literature.[@R7] There is rising concern about the limited accountability of missions, with little data reported back to healthcare authorities due to a lack of outcome measurements.[@R8] Quality of care is debated, as missions often have limited capacity to provide ancillary services or follow-up.[@R16] Furthermore, sustainability is questioned in terms of lasting positive impact on the local healthcare system or its cost-effectiveness. The question is whether short-term surgical missions are the most rational allocation of resources to address local healthcare needs.[@R4] Ultimately, the ethical implications of surgical volunteerism often ignite debate.[@R17]

These concerns are discussed in several reviews of medical missions in low-income and middle-income countries (LMICs).[@R7] For instance, Martiniuk *et al* and Roche *et al* argued that global standards are needed for short-term medical missions,[@R7] and Sykes shows that only 6% of all published studies on medical missions report on empirical data.[@R10] Only a few studies reviewed surgical missions specifically.[@R9] Shrime *et al* systematically compare three types of charitable platforms for global surgery (short-term missions, self-contained surgical platforms and specialty surgical hospitals run by non-governmental organisations \[NGOs\]). Although they conclude that evidence in the literature is scarce, they state that self-contained temporary platforms and specialised surgical centres appear to provide more effective and cost-effective care than short-term surgical missions, except when no other delivery platform exists.[@R12]

These reviews provide valuable insights into medical missions in general. However, the diversity of medical and surgical missions is large, which hampers the interpretation of empirical data. This review aims to systematically review evidence on the impact of short-term reconstructive surgical missions specifically, and critically analyses the quality of the available empirical data. In this review, four key aspects are addressed: basic characteristics of missions, patient safety, health gains of individuals and sustainability.

Methods {#s2}
=======

We conducted a systematic review of the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines.[@R20]

Inclusion criteria {#s2-1}
------------------

All original studies that analysed empirical data of short-term missions pertaining to reconstructive surgical care in LMICs were eligible. Studies lacking analyses of empirical data, reviews, studies of specialty surgical hospitals that provide continuous year-round care, mobile surgical platforms sent from in-country hospitals, studies in conflicts zones, studies not related to LMICs or studies of patients that were transported to high-income countries (HICs) were excluded. The studies were restricted to English and Dutch language. No restrictions were applied regarding publication dates. Duplicates were excluded.

Search strategy and data sources {#s2-2}
--------------------------------

PubMed, Embase.com, Clarivate Analytics/Web of Science and Open Grey were searched up to 1 July 2018; Proquest up to 1 July 2017 (by CR, TH and JK). The last database was no longer available to us after 2017. The following terms---including synonyms---were used as index terms or free-text words: 'plastic surgery', 'reconstructive surgical procedures', 'cleft lip', 'post-burn contractures' or 'noma' combined with 'medical missions', 'humanitarian' or 'charity'. More studies were identified by reviewing the bibliographies of retrieved studies. The full search strategies for all databases can be found in the [online supplementary file 1](#SP1){ref-type="supplementary-material"}.
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Study selection {#s2-3}
---------------

Studies were screened for eligibility by two independent investigators (TH and CR): in case of disparity, a third author was involved (MB). Two investigators independently extracted the data to create tables and figures (TH and CR).

Data on mission characteristics and individual patient-level data were extracted and analysed across four key features:

1.  Basic characteristics of the missions, including mission length, number of patients who received surgery, and age and gender distribution.

2.  Patient safety by means of complication registration. Data were collected on three indicators: follow-up length, follow-up rate and complication rate. The follow-up rate was calculated by the number of patients who completed follow-up divided by the total number of patients who were included for follow-up. The complication rate was calculated as follows: the number of patients with complications divided by the total number of patients who completed follow-up.

3.  Health gains: data on surgical outcomes were collected, for example, improvement of range of motion, patient-reported outcome measures (PROMs) or DALYs averted per patient. All reported PROMs were recorded, for example on surgical outcomes, complications or the quality of care provided. All types of formats, questionnaires or any other tool describing these outcomes were included.

    DALYs are used to define the overall disease burden over a population and are calculated by 'adding the number of years of life lost due to premature mortality to the number of years of healthy life lost related to disability'.[@R21] This means that 1 DALY can be defined as one lost year of healthy life.[@R21] Many limitations of this approach are described in the literature. The biggest challenge is that it is not based on health data from countries, but on complex estimation techniques. DALYs are therefore estimations and many concerns exist about their reliability and uncertainty.[@R22] Despite these challenges, DALY metrics are commonly applied in global surgery studies.[@R1]

4.  Sustainable characteristics of missions: studies were reviewed for data on long-term partnerships, training objectives and involvement of local staff. Also, data on the cost-effectiveness of missions were collected. Missions were categorised either as stand-alone or consecutive missions to the same hospital, region or country.

Data analysis and synthesis {#s2-4}
---------------------------

After a pilot, data were extracted independently and in duplicate using a data extraction sheet (TH and CR). Authors were contacted when data on complication registration were missing. Quantitative data synthesis consisted of compiling total number of patients (eg, total number of patients who were included, total number of patients with complications) to generate overall outcomes. [Table 1](#T1){ref-type="table"} and the [online supplementary appendix file 1](#SP1){ref-type="supplementary-material"} provide details of the data extracted from each reference. Due to the heterogeneity of studies in types of surgery, local healthcare settings or available resources, statistical analyses were not feasible. Study quality assessment was performed independently by authors TH and CR according to the Oxford CEBM Level of Evidence classification[@R25] and the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system.[@R26]

###### 

Study characteristics

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors (year)                           Affiliated organisations                                 Country of mission                                                               Year of mission   Number of patients treated^a^   Length of follow-up^b^                  Follow-up rate        Complication rate^c^   Health gains
  ---------------------------------------- -------------------------------------------------------- -------------------------------------------------------------------------------- ----------------- ------------------------------- --------------------------------------- --------------------- ---------------------- ------------------------------------------------------------------------------------------------
  **Clefts**                                                                                                                                                                                                                                                                                                                

  Aziz *et al* (2009)[@R27]                NA                                                       Bangladesh                                                                       2006--2008        146                             ≤10 days                                NA                    8/146 (5.5%)           NA

  Bello *et al* (2018)[@R28]               CFDF                                                     Nigeria                                                                          2011--2017        448                             2 months                                155/448 (34.6%)       35/155 (34.6%)         NA

  Bermudez and Lizarraga (2009)[@R69]      Operation Smile                                          40 countries                                                                     2007              4086                            1 year                                  812/4086 (19.9%)      NA                     NA

  Calis *et al* (2016)[@R33]               Interplast Turkey                                        Uzbekistan                                                                       2009--2014        529                             NA                                      NA                    1/529 (0.2%)           NA

  Daniels *et al* (2016)[@R34]             ReSurge Int.                                             China                                                                            2005--2009        201                             1--5 years^b^                           116/201 (57.7%)\*     34/96 (35.4%)\*        NA

  Fayyaz *et al* (2015)[@R36]              Cleft Lip and Palate Association Pakistan                Pakistan                                                                         2014              312                             3 months                                NA                    18/312 (5.8%)          NA

  Guneren *et al* (2015)[@R40]             Turkish international development agency^a^              Asia, Middle East, Africa                                                        2007--2014        25                              NA                                      NA                    NA                     NA

  Hackenberg *et al* (2015)[@R41]          Operation Smile                                          India                                                                            2006--2012        3503                            NA                                      NA                    NA                     Total 21 006 DALYs averted\
                                                                                                                                                                                                                                                                                                                            6.0 DALYs averted per patient

  Hughes *et al* (2016)[@R42]              Hands Across the World                                   Ecuador                                                                          2015              27                              NA                                      NA                    NA                     NA

  Hughes *et al* (2012)[@R43]              Hands Across the World                                   Ecuador                                                                          1996--2011        1142                            7 days                                  1089/1142 (97.1%)\*   40/1122 (3.6%)\*       Total 396--1042 DALY averted\
                                                                                                                                                                                                                                                                                                                            3.9--10.2 DALY averted per patient

  MacIntosh *et al*, (2013)[@R46]          Healing the Children                                     Colombia                                                                         1994--2011        2558                            NA                                      NA                    10/2727 (0.4%)^d^      NA

  Madsen *et al* (2015)[@R47]              US military                                              Dominican Republic                                                               2005--2009        223                             30 months                               205/223 (91.1%)       13/223 (5.8%)          Speech score improved from 11.4 (6--24) to 5 postoperatively (borderline=6)

  Magee *et al* (2010)[@R48]               Operation Smile                                          Kenya, Russia, Nicaragua, Vietnam                                                2008              303                             NA                                      NA                    NA                     Total 3099.52 DALYs averted\
                                                                                                                                                                                                                                                                                                                            10.1 DALYs averted per patient

  Maine *et al* (2012)[@R49]               ReSurge Int and Rostros Felices                          Ecuador                                                                          2000--2005        315                             \>14 days                               128/315 (40%)         72/128 (56.3%)         NA

  McQueen *et al* (2007)[@R53]             Operation Smile                                          Jordan, Iraq                                                                     2005              71                              NA                                      NA                    4/71 (5.6%)            NA

  McQueen *et al* (2009)[@R67]             Operation Smile                                          18 Countries                                                                     NA                8151                            NA                                      NA                    67/8151 (0.8%)         NA

  Moon *et al* (2012)[@R55]                Smile for Children                                       Vietnam                                                                          2007--2010        303                             NA                                      NA                    NA                     Total 377 to 458 DALYs averted on average mission

  Navarro (2015)[@R56]                     CIRPLAST                                                 Peru                                                                             1994--2014        6108                            12 days (range 12 days to 9 years)^b^   5162/6108 (84.5%)     377/5162 (7.3%)        NA

  Park *et al* (2018)[@R39]                Operation Smile                                          India                                                                            2010--2011        890                             7 days                                  662/890 (74.4%)       101/662 (15.3%)        NA

  Rauso *et al* (2015)[@R57]               Emergenza Sorrisi Onlus                                  Uganda, Gabon                                                                    2012--2014        56                              NA                                      NA                    2/56 (3.6%)            NA

  Rivera *et al* (2013)[@R58]              Operation Smile                                          Honduras                                                                         2007              45                              6 months                                22/45 (48.9%)         3/22 (13.6%)           NA

  de Buys Roessingh *et al* (2012)[@R16]   SedoGoho hospital, TdH, CHUV Laus.                       Benin and Togo                                                                   1993--2008        131\*                           5.6--7.6 years                          36/71 (50.7%)\*       14/71 (19.7%)\*        Speech follow-up: 36 patients. Acceptable 17/36=47.2%. Unacceptable 19/36=52.8%

  Rossell-Perry *et al* (2015)[@R60]       ReSurge International and Smile Train                    Peru                                                                             2002--2012        257                             1--5 years^b^                           97/353 (27.5%)^d^     34/257 (13.2%)\*       NA

  Sharp *et al* (2008)[@R61]               Operation Smile                                          Philippines                                                                      2003              120                             6 months                                52/99 (52.5%)\*       10/50 (20.0%)\*        Improved speech 52%Improved eating 25%Improved social benefit 14%Improved appearance 6%

  Sieg *et al* (2004)[@R62]                NA                                                       Africa, Asia, Central America                                                    NA                14                              ≥1 year                                 10/14 (71.0%)\*       1/10 (10%)\*           NA

  Uemura *et al* (2015)[@R64]              Duang-Kaew Foundation                                    Thailand, Vietnam, Myanmar, Laos, Cambodia, China, Sri Lanka, Bhutan and India   1988--2008        6832                            1 month                                 5412/6832 (79.2%)     186/5412 (3.4%)        NA

  Uetani *et al* (2006)[@R65]              Japanese Cleft Palate Foundation                         Vietnam                                                                          1993--2003        790                             NA                                      NA                    NA                     NA

  Wes *et al* (2017)[@R66]                 Changing Children\'s Lives Int.                          Thailand                                                                         2013              56                              \<1.5 years                             30/56 (53.6%)         0/30 (0%)              Self-reported improvement: social interactions 83,3%; confidence 83.3%; school performance 75%

  **Post-burn contracture**                                                                                                                                                                                                                                                                                                 

  Borghese *et al* (2005)[@R31]            NA                                                       Cambodia, Bangladesh                                                             2002, 2003        200                             NA                                      NA                    14/200 (7.0%)          NA

  El Ezzi *et al* (2017)[@R35]             Terre des Hommes                                         Benin and Togo                                                                   2002--2011        50                              3.6 years                               50/50 (100%)          28/50 (56.0%)          NA

  Fuzaylov *et al* (2015)[@R38]            Doctors Collaborating to Help Children                   Ukraine                                                                          2011--2013        39                              NA                                      NA                    1/39 (2.6%)            NA

  Kim *et al* (2012)[@R45]                 Operation ReStore, Operation Smile and Cents of Relief   India                                                                            2010              38                              NA                                      NA                    9/60 (15.0%)           NA

  Sinha *et al* (2016)[@R63]               Operation ReStore                                        India                                                                            2012              31                              84 days                                 31/39 (79.5%)         9/31 (29.0%)           SF-36 QoL : improvement of 5.8 points\
                                                                                                                                                                                                                                                                                                                            WPI: 13.7% mean improvement

  **Noma**                                                                                                                                                                                                                                                                                                                  

  Bouman *et al* (2010)[@R32]              Facing Africa and Dutch Noma Foundation                  Ethiopia, Nigeria                                                                2007, 2008        63                              35 days                                 74/74 (100%)^d^       47/74 (63.5%)^d^       Excellent results 36%\
                                                                                                                                                                                                                                                                                                                            Satisfactory 23%\
                                                                                                                                                                                                                                                                                                                            Mediocre 16%\
                                                                                                                                                                                                                                                                                                                            Poor 11%\
                                                                                                                                                                                                                                                                                                                            Very poor 14%

  Marck *et al* (2010)[@R50]               Facing Africa                                            Ethiopia                                                                         2007, 2008        77                              35 days                                 77/77 (100%)          54/77 (70.1%)          Good results 30.7%\
                                                                                                                                                                                                                                                                                                                            Acceptable 34.6%\
                                                                                                                                                                                                                                                                                                                            Mediocre 17.9%\
                                                                                                                                                                                                                                                                                                                            Poor 7.7%\
                                                                                                                                                                                                                                                                                                                            Very poor 9.0%

  McGurk and Marck (2010)[@R52]            Project Harar                                            Ethiopia                                                                         2007--2009        95                              35 days                                 89/95 (94%)           57/89 (64.0%)          Simple surgery group: good or acceptable results 90%\
                                                                                                                                                                                                                                                                                                                            Complex surgery group: good or acceptable results 40%\
                                                                                                                                                                                                                                                                                                                            Overall, poor results 6%\
                                                                                                                                                                                                                                                                                                                            Overall, very poor results 6%

  Rodgers *et al* (2015)[@R59]             Facing Africa and Dutch Noma Foundation                  Ethiopia                                                                         2008--2014        34                              36 days                                 NA                    17/34 (50.0%)          NA

  **General reconstructive missions**                                                                                                                                                                                                                                                                                       

  Baran *et al* (2007)[@R29]               Physicians for Peace and Interplast                      Multiple countries                                                               1985--2004        4736                            NA                                      NA                    NA                     NA

  Figus *et al* (2009)[@R37]               Interplast Italy                                         Multiple countries                                                               1988--2008        5235                            NA                                      NA                    NA                     NA

  McClenaghan *et al* (2013)[@R51]         Project Harar                                            Ethiopia                                                                         2012              40                              21 days                                 30/30 (100%)          7/30 (23.3%)           NA

  Merrel *et al* (2007)[@R54]              Operation Smile                                          Vietnam                                                                          1990--2004        266                             NA                                      NA                    6/266 (2.3%)           NA
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Authors were contacted when data were missing for follow-up. Of note, in several studies (indicated with an \*), the follow-up rate or complications rate were calculated over different subgroups; therefore, columns may not add up or correlate. ^a^When available, this review reports the number of patients who received surgery; when not available, the number of procedures was used; when not available, the number of diagnosis was used. ^b^When studies reported a range of follow-up intervals, the shortest length of follow-up was used for calculations. ^c^When the total number of patients who completed follow-up was not available, the total number of patients included was used (in line with the cited articles). ^d^The complication rate cited was calculated over the total number of procedures.

CFDF, Cleft & Facial Deformity Foundation; DALY, disability-adjusted life year; NA, not available; SF-36 QoL, 36-Item Short Form Health Survey on Quality of Life; WPI, Whole Person Impairment questionnaire.

Results {#s3}
=======

The search identified 1662 unique citations. After screening titles and abstracts 1570 studies were excluded because they did not concern short-term reconstructive surgical missions. Ninety-two studies concerned reconstructive surgical missions and were reviewed full-text. Of the full-text studies, 51 were excluded. Please see figure 1 for the screening and selection process. Studies reviewing specialty hospitals missions were excluded, as this was outside the scope of this review. After full-text analyses, 41 met full inclusion criteria ([figure 1](#F1){ref-type="fig"} and [table 1](#T1){ref-type="table"}).[@R27]

![Flow diagram. LMIC, low-income and middle-income country.](bmjgh-2018-001176f01){#F1}

The studies included predominantly consisted of case series, with 37 studies graded at Oxford CEBM Level IV. The remaining four economic analyses were graded at level IIB. This resulted in a C grade of recommendations for our review, according to CEBM. The overall GRADE score was 2.7 (low to moderate quality), meaning that our confidence in the effect estimate is limited ([table 2](#T2){ref-type="table"}).[@R26]

###### 

Quality assessment results

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Type of missions                                 Number of studies included   Oxford CEBM Level of Evidence        Average GRADE score
  ------------------------------------------------ ---------------------------- ------------------------------------ ------------------------------
  Cleft care mission studies                       28 studies                   24 Level IV studies (case series)\   2.6 (quality: low--moderate)
                                                                                4 Level IIB (economic studies)       

  Post-burn contractures mission studies           5 studies                    5 Level IV studies (case series)     3.4 (quality: moderate)

  Noma mission studies                             4 studies                    4 Level IV studies (case series)     4.3 (quality: high)

  General reconstructive surgery mission studies   4 studies                    4 Level IV studies (case series)     1.3 (quality: very low--low)

  Overall quality and level of recommendation      41 studies                   37/41 Level IV studies\              2,7 (quality: low--moderate)
                                                                                4/41 Level IIB studies\              
                                                                                Level C recommendations              
  -------------------------------------------------------------------------------------------------------------------------------------------------

Information listed per condition. Quality assessment of included studies was performed using the GRADE system[@R68] and Oxford CEBM Level of Evidence.

Twenty-eight of 41 studies included pertained to cleft care (78% of the total study population). The number of patients in all studies totalled 48 546, with a mean age of 13.4 years (SD 8.5) ([table 3](#T3){ref-type="table"}). The average mission length was 10 days (SD 3.8; range, 6--21 days). Organisations were active in Africa, South-East Asia, Eastern Europe, and South and Central America. A typical mission team consisted of two or three plastic and/or maxillofacial surgeons, one or two anaesthetists, a mission coordinator, theatre nurse and one or two resident doctors, totalling 8 to 10 individuals for one single mission.[@R32] Some teams were considerably larger, up to 40 individuals.[@R36]

###### 

\(A\) Overall outcomes on basic characteristics of missions

                           Length of mission   Total number of patients   Gender distribution   Age                                                                                                         
  ------------------------ ------------------- -------------------------- --------------------- ----- -------------- --------------------- ---- --------------- --------------- ---- ----------------- ---- -----------------------
  Clefts                   18                  168                        9                     28    37 642 (78)    1344                  18   12 210 (45.8)   14 435 (54.2)   12   9.22              3    4.5
  Post-burn contractures   3                   23                         8                     5     358 (1)        72                    4    143 (44.8)      176 (55.2)      2    27.6              1    4.0
  Noma                     2                   28                         14                    4     269 (1)        67                    3    102 (58.6)      72 (41.4)       1    23.9              1    17.0
  General reconstructive   4                   57                         14                    4     10 277 (21)    2569                  1    143 (44.8)      176 (55.2)      1    24.0              NA   NA
  Totals                   27                  276                                              41    48 546 (100)                         26   12 598 (45.9)   14 859 (54.1)   16                     5    
  Overall mean or median                                                  10 (+/-SD 3.8)                             1184 (+/-SD 2134.4)                                             13.4 (SD+/-8.5)        4.5 (Q~25-75~ 2.9-13)

  \(B\) Overall outcomes on patient safety                                                                                                                
  ------------------------------------------ -------- ---- --------------------------- -------- ---------- -------------------------- -------- ---------- ------------------------
  Clefts                                     7        NA   111/11 992 (0.9)            6        81.0       739/12 513 (5.9)           9        54.3       181/887 (20.4)
  Post-burn contractures                     3        NA   24/383 (6.3)                1        77.4       9/31 (29.0)                1        100.0      28/50 (56.0)
  Noma                                       1        NA   17/34 (50.0)                3        97.6       158/240 (65.8)             0        NA         NA
  General reconstructive                     1        NA   6/266 (2.3)                 1        100        7/30 (23.3)                0        NA         NA
  Total studies                              **12**                                    **11**                                         **10**              
  Overall rate                                             **158/12 675** (**1.25**)            **81.3**   **913/12 814** (**7.1**)            **56.0**   **209/937** (**22.3**)

\*The follow-up rate: the number of patients who completed follow-up divided by the total number of patientsi ncluded for follow-up. For clarity reasons only percentages are displayed, patients numbers are omitted.

†The complication rate: the number of patients with complications divided by the total number of patients who completed follow-up. Displayed are the patient numbers, between brackets the complication percentage.

NA, not available.

Regarding patient safety, nine studies (22%) did not report on complications. Twelve studies (29%) only reported a complication rate without reporting on follow-up length or rate. The overall complication rate in these 12 studies was 1.2%. Ten studies (24%) reported a follow-up length shorter than 180 days, with a mean follow-up rate of 81.3% and a complication rate of 7.1%. Ten studies (24%) provided a follow-up length longer than 180 days, reporting a mean follow-up rate of 56.0% and a 22.3% complication rate ([table 3](#T3){ref-type="table"}). Mortality after cleft surgery was reported in three studies, totalling 3 out of 14 551 patients included in these studies.[@R16] For general reconstructive surgical missions---not specified for a single disease---one single study reported one death[@R54] and no mortality was reported in contracture and noma missions.

Twelve studies (29%) reported on health gains of the mission, reporting heterogeneous methods and outcomes ([table 1](#T1){ref-type="table"}). Methods used in cleft studies included photographic assessment of aesthetic outcomes,[@R30] speech evaluation[@R16] or DALYs averted.[@R41] Three cleft studies evaluated speech functionality postoperatively, either by questionnaires[@R61] or speech tests.[@R16] Study methods were clear and showed overall improvements of speech. Four cleft studies reported on DALYs averted by cleft lip and palate repair surgery. DALYs averted per patient were 3.9,[@R43] 6.0[@R41] and 10.1 per patient.[@R48] In three noma missions, a surgeon-reported outcome scale was used to score aesthetic and functional outcome.[@R32] Overall findings showed that high-complex surgery is associated with greater risks of unsatisfactory results. Three studies used PROMs. One contracture study reported improvements in quality of life and disability by using validated questionnaires, and reported overall positive outcomes.[@R63] Two cleft studies used self-developed questionnaires to assess PROMs, reporting positive results.[@R61] None of the studies reported on patient-reported outcomes on the quality of the care provided.

With regard to the sustainable characteristics of missions, 29 studies reported qualitative data (71%) on sustainability, while none of the studies reported quantitative data. Fifteen out of twenty studies that reported on follow-up and complications also reported on sustainable characteristics such as long-term partnerships or training activities ([table 4](#T4){ref-type="table"}). Ten organisations (24%) were engaged in longer-term partnerships, and thirteen missions (32%) returned to the same regions or hospitals. Few data were available on the frequency of missions, although several studies reported conducting yearly missions.[@R32] Fifteen studies (35%) described teaching objectives as a goal during their missions. Activities mentioned were lectures,[@R29] training of local surgeons,[@R16] healthcare workers[@R47] or fellowships in donor countries.[@R16] However, none of the studies published empirical data on the effects of training or elaborated on how the training of local healthcare personnel was organised.

###### 

Sustainable characteristics of short-term missions

  Authors (year)                           Years           Number and frequency   Long-term relationship   Teaching objective       Advancement of local staff   Quality follow-up and sustainable characteristics†                                                                                                                                                                             
  ---------------------------------------- --------------- ---------------------- ------------------------ ------------------------ ---------------------------- ---------------------------------------------------- ------------------------ ----------------------- ----------------------- ----------------------- ------------------------ ----------------------- ----------------------- -----------------------------------------------------------------------------------
  Aziz *et al* (2009)[@R27]                2006--2008      3 (annual)             ✓                                                 ✓                            ✓                                                    ✓                                                                                                ✓                                                                        
  Bello *et al* (2018)[@R28]               2011--2017      17                     ✓                        ✓                                                                                                          ✓                                                                                                ✓                                                                        ■
  Baran *et al* (2007)[@R29]                                                      ✓                        ✓                        ✓                                                                                 ✓                        ✓                                               ✓                       ✓                        ✓                       ✓                       
  Bermudez *et al* (2009)[@R30]            2007                                                                                                                  ✓                                                                                                                                                     ✓                                                                        
  Borghese *et al* (2005)[@R31]            2002--2003                             ✓                                                                                                                                                                                                                                                                                                             
  Bouman *et al* (2010)[@R32]              2007--2008      4 (biannual)           ✓                                                                                                                                                                                                                                                                                                             ■
  Calis *et al* (2016)[@R33]               2009--2014      6 (annual)             ✓                        ✓                        ✓                                                                                                                                                                                  ✓                                                ✓                       
  Daniels *et al* (2016)[@R34]                                                    ✓                                                 ✓                                                                                                                                                                                                                                                           ◊
  El Ezzi *et al* (2017)[@R35]             2002--2011      9 (biannual)           ✓                        ✓                        ✓                            ✓                                                    ✓                                                ✓                                               ✓                        ✓                       ✓                       ◊
  Fayyaz *et al* (2015)[@R36]              2004--present   130                    ✓                        ✓                        ✓                                                                                                                                                                                  ✓                                                ✓                       
  Figus *et al* (2009)[@R37]               1988--present   47                     ✓                                                                                                                                   ✓                        ✓                                               ✓                       ✓                                                                        
  Fuzaylov *et al* (2015)[@R38]            2011--2013      3 (annual)             ✓                        ✓                                                     ✓                                                    ✓                        ✓                                                                       ✓                                                ✓                       
  Guneren *et al* (2015)[@R40]             2007--2014      27                                                                       ✓                                                                                                                                                                                  ✓                                                ✓                       
  Hughes *et al* (2012)[@R43]              1996--2011      16 (annual)            ✓                                                                              ✓                                                                                                                                                                                                                              ■
  MacIntosh *et al* (2013)[@R46]           1993--present   (biannual)             ✓                                                                                                                                   ✓                                                                                                ✓                                                                        
  Madsen *et al* (2015)[@R47]              2005--2009      (annual)               ✓                        ✓                                                                                                                                   ✓                                                                       ✓                                                                        ◊
  Maine *et al* (2012)[@R49]               2000--2005                                                                                                            ✓                                                                                                                                                                                                                              ◊
  Marck *et al* (2010)[@R50]               2007--2008      2 (annual)             ✓                        ✓                        ✓                                                                                                                                                                                                                                                           ■
  McClenaghan *et al* (2013)[@R51]         2012                                   ✓                        ✓                                                                                                                                                                                                                                                                                    ■
  McQueen *et al* (2007)[@R53]             2005                                                                                                                                                                                                ✓                                                                       ✓                                                                        
  Merrel *et al* (2007)[@R54]              1990--2004      11                     ✓                        ✓                                                                                                          ✓                        ✓                                                                                                ✓                                               
  Moon *et al* (2012)[@R55]                2007--2010      4 (annual)             ✓                                                                                                                                   ✓                        ✓                                               ✓                       ✓                                                ✓                       
  Navarro (2015)[@R56]                     1994--2014      141 (10 annually)      ✓                                                                                                                                                                                                                                                                                                             ■
  Park *et al* (2018)[@R39]                2010--2011      2                      ✓                        ✓                                                     ✓                                                    ✓                                                ✓                       ✓                       ✓                                                                        ■
  Rivera *et al* (2013)[@R58]              2007            1                                                                                                                                                                                                                                                           ✓                                                                        ◊
  de Buys Roessingh *et al* (2012)[@R16]   1993--2008      (annual)                                                                                              ✓                                                    ✓                        ✓                       ✓                                                                        ✓                       ✓                       ◊
  Rossell-Perry *et al* (2015)[@R60]       2002--2012                             ✓                        ✓                        ✓                            ✓                                                    ✓                                                                                                                                                                         ◊
  Uemura *et al* (2015)[@R64]              1988--2008      458                    ✓                                                                                                                                                                                    ✓                                               ✓                                                                        ■
  Uetani *et al* (2006)[@R65]              1993--2003                             ✓                        ✓                                                                                                          ✓                                                                                                ✓                                                ✓                       
                                                                                  Reported by 23 studies   Reported by 13 studies   Reported by 9 studies        Reported by 9 studies                                Reported by 13 studies   Reported by 8 studies   Reported by 4 studies   Reported by 4 studies   Reported by 18 studies   Reported by 4 studies   Reported by 9 studies   Reported by 15 studies (75%) of all 20 studies that reported on follow-up details

In order to determine whether or not missions were sustainable, the data were collected and allocated to three groups, ie, building long-term relationships, teaching objectives during the mission and the advancement of local staff. Each sustainability group is divided into different subsets. A checkmark (✓) means the study describes the concomitant form of sustainable health care.

\*Part of the Operation Smile International (OSI) programme.

†Added to this table were studies that reported both on sustainable[@R27] characteristics and on quality of follow-up (including length and rate of follow-up and complication rate). Eight studies with follow-up shorter than 180 days (■ marks), seven studies with follow-up[@R29] up longer than 180 days (◊ marks). Five studies reported on quality of follow-up, but did not report on sustainable characteristics.

Four cost-effectiveness studies were available for short-term cleft missions. Three studies reviewed the effectiveness per DALY averted, reporting US\$33.94/DALY,[@R48] US\$56.0/DALY[@R55] and US\$247.42/DALY.[@R41] The variation is explained by the differences in study populations, sample sizes, effectiveness measurements and 'costing approaches' used.

Discussion {#s4}
==========

Several systematic reviews about short-term medical missions are available.[@R7] This is the first systematic review that specifically assesses the quality of available data on short-term reconstructive surgical missions.

Although all the studies included in our review reported a positive impact of surgical missions, the level of evidence remains low. It seems that follow-up of treated patients is a challenge. Although a majority of studies provide data on complication rates, the varying quality of this outcome measure makes it difficult to draw any conclusions. The results showed that reported complication rates were considerably higher when the quality and length of follow-up increased. This suggests that without data on quality of follow-up, there is a high risk of reporting bias due to under-reporting of complications. This also means that without comprehensive information on follow-up, the safety of missions is likely to be overestimated.

Furthermore, studies used different control groups to benchmark their respective findings with regard to complication rates. Three of cleft care studies included compared complications between mission patients and patients who underwent similar procedures in a HIC. Results showed substantially higher complication rates in mission patients.[@R34] One study showed that fistula risk was 15.6 times that for a US cohort.[@R34] Maine *et al* [@R49] state that complication rates were 20 times higher in the mission cohort compared with a US cohort, independently of whether the surgery was performed by Ecuadorian or American surgeons. It should be mentioned that comparisons of complication rates between HICs and LMICs cannot be made without taking into consideration that HICs have more resources at their disposal to limit complications. Therefore, we would suggest developing benchmark complication rates of LMICs, which can be used to assess the outcomes of short-term missions.

Some authors argue that longer-term specialty surgical hospitals may be provide more effective care than short-term missions.[@R9] Specialty hospitals provide continuous care all year round in a LMIC. The cleft care centre of Operation Smile in India,[@R39] or Smile Train's model are examples of this approach.[@R69]

Both organisations report lower complication rates than those reported in short-term missions. The centre of Operation Smile reports a short-term complication rate of 4.0% (cleft lip repair) and 15.8% (cleft palate repair), which is lower than the rates of their counterpart short-term missions.[@R39] Smile Train studies report lower rates, between 0.88% and 3%.[@R70] However, they note that there might be a risk of under-reporting or selection bias due to a dependence of Smile Train surgeons on payment-per-patient (risking fewer referrals when higher complication rates are reported) and a limited capacity of surgeons to treat complex cases.[@R70] Furthermore, with only one Smile Train study reporting on follow-up lengths,[@R73] these complication rates should be interpreted with caution. To be able to compare the strengths and weaknesses of different approaches of providing surgical care in a LMIC, there is a need for more high-quality studies.[@R12] Apart from registrations of complications, such studies should assess long-term outcome using validated outcome measures and PROMs. Specialty hospitals, which provide services all year round, could provide good conditions for longer-term outcome research.

Several studies in this review consistently report on follow-up, showing that substantial efforts are being made to improve the data output of missions.[@R16] Ten studies reported significant follow-up lengths of more than 6 months and high numbers of patients returning for follow-up were shown.[@R16] The majority of these missions were engaged in long-term partnerships. This included training of local healthcare personnel, which was likely to improve the feasibility of organising follow-up. Several strategies were implemented to ensure the quality of follow-up. Some missions deployed medical students to assess palate fistulas[@R34] or sent a speech pathologist in-country to review outcomes.[@R61] Others trained local surgeons on follow-up and revision surgery.[@R54] The relatively high number of complications seen in noma missions could be partly explained by a stringent follow-up, done by an independent researcher who consistently reported on follow-up. All the studies mentioned above provide examples of how to ensure patient safety during and after missions.[@R50]

Although some studies reported on health gains, with several studies reporting positive functional outcomes,[@R16] the methods and evidence are heterogeneous and results are too limited to draw conclusions. The role of PROMs are effective in reconstructive surgery to assess the quality and outcomes of healthcare.[@R80] Only few of the studies included reported successfully on outcomes using PROMs[@R61] and none assessed the quality of care experienced by patients. Patient experience of outcomes and quality is important.[@R82] Future studies should include PROMS on surgical outcomes and quality of care. Only a few studies report on the sustainable characteristics of missions. Data on this topic are usually qualitative and highly variable. It is noteworthy that reporting on sustainability and higher quality of patient follow-up often go hand in hand. This suggests that more sustainable missions may be better able to follow their patients for a longer period. However, as empirical evidence on sustainability is still non-existent, there is an urgent need for further studies.[@R12]

Limitations {#s4-1}
-----------

This systematic review has several limitations. Literature on short-term reconstructive missions is scarce and of limited quality, limiting the strength of this review.[@R25] As the majority of studies are cleft studies, the conclusions and recommendations of this review may not be fully applicable to other types of reconstructive surgical missions.

The studies included represent just a small proportion of the many reconstructive surgical missions conducted worldwide. This may introduce a potential bias. It is likely that the small proportion likely does not fully represent the actual effect of all reconstructive surgical missions. In our view, this emphasises the need to incorporate standard monitoring and evaluations into missions.

Furthermore, this review addresses only short-term missions and does not attempt to make a direct comparison with long-term surgical platforms such as specialty hospitals. It is often argued that specialty hospitals are safer and have a more positive effect on local healthcare systems.[@R12] Comparative studies of short-term missions and specialty hospitals can identify strengths and weaknesses of each approach. However, a definitive comparison between missions and specialty hospitals seems to be premature at present given the lack of comparative studies.[@R12]

Concerns regarding the use of DALY metrics are applicable to the studies included in this review. It is argued that surgical conditions are underestimated in the global burden of disease studies.[@R1] Attempts to estimate the surgical burden across all disease conditions have been challenging.[@R85] In a recent study, it was argued that the current DALY approach is inadequate to quantify the burden of paediatric surgical conditions.[@R87]

Recommendations {#s4-2}
---------------

There are opportunities for NGOs to develop short-term missions towards more sustainable partnerships. In the past, missions have been a 'vertical' approach to healthcare development.[@R4] Such missions have limitations, for example in building local capacity of surgical services. The results of this study indicate that longer-term follow-up is frequently lacking, with complications being potentially missed. To address these shortcomings, the 'diagonal development' approach has been proposed.[@R4] It combines the short-term vertical inputs of missions with longer-term horizontal benefits, with the ultimate aim of improving access to, and surgical capacity of, the local healthcare system. Such goals may be achieved through long-term development of surgical infrastructure, continued training of the local surgical workforce or building an academic culture.[@R4]

One example of such a diagonal approach is to aim for standardised tracking of longer-term outcomes of missions in strong collaboration with local partners. This might yield several advantages. Besides empowering local researchers and building an academic culture, outcomes can be reported back to patients and healthcare authorities. This will enhance the accountability of NGOs[@R8] and allow for evaluations of the quality of care provided.

Another example of long-term investments in the local surgical capacity is strengthening of the training activities of surgical NGOs. Such activities should be integrated into existing national or regional training activities. The training should be adapted to local settings, needs-driven and should focus on bilateral knowledge exchange.[@R4]

Conclusion {#s5}
==========

This review shows that evidence for the effectiveness of short-term reconstructive surgical missions is both of limited substance and quality. Given the overall lack of evidence, there is an urgent need to incorporate outcomes research in future missions. This should include longer-term complication registration and measurements of health gains among individual patients. The effectiveness of training activities should also be evaluated. One approach to achieve this is to develop short-term missions towards diagonal development missions, which aim to build surgical capacity of local healthcare systems through long-term investments.
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